NEW YORK – Japan-based Daiichi Sankyo today announced that it had submitted a supplemental new drug application to Japan's Ministry of Health, Labor, and Welfare for its HER2-directed antibody drug conjugate, trastuzumab deruxtecan (Enhertu), for the treatment of patients with HER2-positive metastatic gastric cancer.